What ovarian cancer screening strategy should be used for women, specifying recommendations for average‑risk individuals (no family history of breast or ovarian cancer, no pathogenic BRCA1 or BRCA2 mutation, no prior pelvic malignancy) and for high‑risk individuals (documented pathogenic BRCA1 or BRCA2 mutation, strong family history of ovarian or breast cancer, or Lynch syndrome)?

Ovarian Cancer Screening: Evidence-Based Recommendations

Do Not Screen Average-Risk Women

The USPSTF issues a Grade D recommendation against ovarian cancer screening in asymptomatic women without known genetic mutations—screening causes more harm than benefit and does not reduce mortality. 1

Why Screening Fails in Average-Risk Women

• The largest randomized trial (PLCO, n=78,216) demonstrated no mortality benefit from annual CA-125 and transvaginal ultrasound screening, with a relative risk of 1.18 (95% CI 0.82-1.71) for ovarian cancer death 2
• The UKCTOCS trial (n=202,638) similarly showed no significant mortality reduction with either CA-125 ROCA algorithm (HR 0.89,95% CI 0.74-1.08) or transvaginal ultrasound (HR 0.91,95% CI 0.76-1.09) 2
• Screening does not detect early-stage disease effectively enough to change outcomes—even when 50% of screened cancers were Stage I versus 5% in controls, this did not translate to survival benefit 1

Substantial Harms of Screening

• False-positive rate is unacceptably high: For every 10,000 women screened annually, 300 women (CA-125) or 350 women (ultrasound) without cancer are recalled for additional testing 3
• Unnecessary surgery is common: 20 women per 10,000 screened with CA-125 or 65 women per 10,000 screened with ultrasound undergo surgery despite having no cancer 3
• Positive predictive value is only 2% in average-risk women, meaning 98% of positive screening tests are false positives 1
• Major surgical complications occur in 3-15% of women undergoing surgery for false-positive results 2

---

Do Not Screen Women with Family History Alone

Even women with a family history of ovarian cancer should not undergo routine screening—the same lack of mortality benefit applies, and harms remain substantial. 1, 3

Evidence in Family History Populations

• In the PLCO trial, 17% of participants had a family history of ovarian or breast cancer; no mortality benefit was observed in this subgroup 1
• Despite higher absolute risk (lifetime risk increases from 1.6% to 5% with one first-degree relative), screening still does not reduce deaths 1, 3
• The false-positive rate and surgical complications remain problematic even in higher-risk populations 3

---

Appropriate Management by Risk Category

Average-Risk Women (No Family History, No Genetic Mutations)

Do not order CA-125, transvaginal ultrasound, HE4, or ROMA as screening tests. 3

• Focus on symptom awareness rather than screening: educate patients about bloating, pelvic/abdominal pain, early satiety, difficulty eating, and urinary urgency/frequency occurring ≥12 days per month 3
• When concerning symptoms arise, perform diagnostic evaluation (not screening) with pelvic examination, CA-125, or transvaginal ultrasound 3
• Discuss proven risk-reduction strategies: oral contraceptive use reduces ovarian cancer risk by approximately 50%, and pregnancy, breastfeeding, and bilateral tubal ligation also provide protection 3, 4

Women with Family History (But No Known Mutation)

Refer for genetic counseling rather than ordering screening tests. 1, 3

Genetic Counseling Referral Criteria:

• Two or more first- or second-degree relatives with ovarian cancer, or a combination of breast and ovarian cancer in the family 1, 4
• For Ashkenazi Jewish women: one first-degree relative or two second-degree relatives on the same side with breast or ovarian cancer 1, 4
• Any woman with a personal history of epithelial ovarian, tubal, or peritoneal cancer regardless of family history 4

Why Genetic Counseling Matters:

• BRCA1 mutations confer a 48.3% cumulative lifetime risk of ovarian cancer by age 70 4
• BRCA2 mutations confer a 20.0% cumulative lifetime risk by age 70 4
• Lynch syndrome confers >12% cumulative risk with earlier age of diagnosis 4
• If a BRCA mutation is confirmed, management changes entirely—these women should be offered risk-reducing bilateral salpingo-oophorectomy, not screening 5, 6

---

High-Risk Women with Confirmed BRCA Mutations or Lynch Syndrome

For women with documented pathogenic BRCA1/BRCA2 mutations or Lynch syndrome who decline or defer risk-reducing surgery, consider surveillance with transvaginal ultrasound plus CA-125 every 6 months starting at age 35. 3

Critical Caveats:

• This is not standard screening—it is intensive surveillance in a very high-risk population 3
• Ovarian screening does not improve outcomes even in BRCA carriers; the evidence shows most tumors detected are still advanced-stage 7, 6
• The UK Familial Ovarian Cancer Screening Study showed better performance characteristics (sensitivity 81.3-87.5%, PPV 25.5%) in women with ≥10% lifetime risk, but no mortality data exist 5
• Risk-reducing salpingo-oophorectomy remains the gold standard for prevention, decreasing ovarian cancer incidence and mortality 8, 6

Timing of Risk-Reducing Surgery:

• BRCA1 carriers: typically between ages 35-40 after childbearing is complete 3
• BRCA2 carriers: typically between ages 40-45 after childbearing is complete 3
• Offer hormone replacement therapy until age 51 in pre-menopausal women without contraindications to minimize detrimental consequences of premature menopause 8
• Risk-reducing surgery prevents 90% of ovarian cancers in BRCA carriers; the remaining 10% arise as primary peritoneal cancers 7

---

Common Pitfalls to Avoid

• Do not order CA-125, HE4, or ROMA as screening tests in asymptomatic women—the FDA and Society of Gynecologic Oncology explicitly state these should not be used for screening 3
• Do not assume family history alone justifies screening—randomized data show no mortality benefit even in higher-risk subgroups 1, 3
• Do not delay genetic counseling referral—this is the appropriate next step for women with significant family history, not ordering tumor markers 3
• Do not confuse diagnostic evaluation with screening—when symptoms prompt concern, CA-125 and ultrasound are diagnostic tools, not screening tests 3
• Do not forget to discuss proven risk-reduction methods: oral contraceptives, pregnancy, breastfeeding, and tubal ligation all reduce ovarian cancer risk 3, 4

---

Emerging Strategies (Not Yet Recommended for Routine Use)

• Risk-reducing early salpingectomy with delayed oophorectomy (RRESDO) is associated with fewer menopausal symptoms and better sexual function than bilateral salpingo-oophorectomy, but should only be offered within research trials 8
• Opportunistic salpingectomy at routine gynecological surgery may be offered to all women who have completed their family, though long-term prospective data on ovarian cancer risk reduction are needed 8
• Population testing to identify high-risk women and novel multicancer early detection biomarkers are under investigation but not ready for clinical implementation 8